Complications of Ovulation Induction

  • Janee A. Fonslick
  • David B. Seifer


Over 2 million women age 15–44 years are estimated to have taken fertility drugs in the United States. This number will continue to increase as more women seek treatment for infertility, and many undergo treatment with ovulation induction agents. Thus it is important to be aware of the possible complications associated with superovulation so we can adequately counsel, diagnose, and treat our patients appropriately. We discuss here several iatrogenic complications associated with the use of ovulation induction agents, including ovarian hyperstimulation syndrome, multifetal gestations, preterm delivery, heterotopic/ectopic pregnancy, spontaneous abortion, and the theoretic risk of a possible increase in the incidence of ovarian cancer.


Ovarian Cancer Epithelial Ovarian Cancer Ectopic Pregnancy Ovarian Stimulation Clomiphene Citrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Antsaklis AJ, Drakakis P, Vlazakis GP, et al. Reduction of multifetal pregnancies to twins does not increase obstetric or perinatal risks. Hum Reprod 1999; 14: 1338–1340.PubMedCrossRefGoogle Scholar
  2. ASRM Practice Committee Report. Guidelines on Number of Embryos Transferred, November 1999.Google Scholar
  3. ASRM Practice Committee Report. Multiple Pregnancy Associated with Infertility Therapy, November 2000.Google Scholar
  4. Bohrer M, Kemmann E. Risk factors for spontaneous abortion in menotropin-treated women. Fertil Steril 1987;48:571–575.PubMedGoogle Scholar
  5. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. Fertil Steril 1996;66:499–507.PubMedGoogle Scholar
  6. Bristow RE, Karlan BY. The risk of ovarian cancer after treatment for infertility. Curr Opin Obstet Gynecol 1996;8:32–37.PubMedGoogle Scholar
  7. Fisch JD, Milki AA, Behr B. Sibling embryo blastocyst development correlates with the in vitro fertilization day 3 embryo transfer pregnancy rate in patients under age 40. Fertil Steril 1999;71:750–752.PubMedCrossRefGoogle Scholar
  8. Fluker MR, Copeland JE, Yuzpe AA. An ounce of prevention: outpatient management of the ovarian hyper-stimulation syndrome. Fertil Steril 2000;73:821–824.PubMedCrossRefGoogle Scholar
  9. Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol vol. 83 p. 619–626, 1996.Google Scholar
  10. Haning RV Jr, Canick JA, Goldsmith LT, et al. The effect of ovulation induction on the concentration of maternal serum relaxin in twin pregnancies. Am J Obstet Gynecol 1996;174:227–232.PubMedCrossRefGoogle Scholar
  11. Hartge P, Schiffman MH, Hoover R, et al. A case control study of epithelial ovarian cancer. Am J Obstet Gynecol 1989;161:10–16.PubMedGoogle Scholar
  12. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926–1930.PubMedCrossRefGoogle Scholar
  13. Hock DL, Scifer DB. Ovarian hyperStimulation syndrome. Infertil Reprod Med Clin North Am 2000; 11:399.Google Scholar
  14. Houmard BS, Scifer DB. Infertility treatment and informed consent: current practices of reproductive endocrinologists. Obstet Gynecol 1999;93:252–257.PubMedCrossRefGoogle Scholar
  15. Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo K-T. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil Steril 1996;65: 552–555.PubMedGoogle Scholar
  16. Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994;9:792–799.PubMedGoogle Scholar
  17. Mathur RS, Akande AV, Keay SD, et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901–907.PubMedCrossRefGoogle Scholar
  18. McElhinney B, McClure N. Ovarian hyperstimulation syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:103–122.PubMedCrossRefGoogle Scholar
  19. Ron EL, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125:780–790.PubMedGoogle Scholar
  20. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771–776.PubMedCrossRefGoogle Scholar
  21. Schenker, et al. Complications of assisted reproductive techniques. Fertil Steril 1994;61:411–422.PubMedGoogle Scholar
  22. Schildkraut JM, Schwingt PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996; 88:554–559.PubMedCrossRefGoogle Scholar
  23. Sherwood OD. Relaxin. In: Knobil E, Neill (eds) The Physiology of Reproduction. New York: Raven, 1988: 585–673.Google Scholar
  24. Shu XO, Brinton LA, et al. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 1989;49:3670–3674.PubMedGoogle Scholar
  25. Spirtas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993;59:291–293.PubMedGoogle Scholar
  26. Strandell A, Thorburn J, Hamberger L. Risk factors for ectopic pregnancy in assisted reproduction. Fertil Steril 1999;71:282–286.PubMedCrossRefGoogle Scholar
  27. Tal J, Haddad S, Gordon N, Timor-Tritsch I. Heterotopic pregnancy after ovulation induction and assisted reproductive technologies: a literature review from 1971 to 1993. Fertil Steril 1996;66:1–12.PubMedGoogle Scholar
  28. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 1995;346:995–1000.PubMedCrossRefGoogle Scholar
  29. Weiss G, Goldsmith LT, Sachdev R, et al. Elevated firsttrimester serum relaxin concentrations in pregnant women following ovarian stimulation predict prematurity and preterm delivery. Obstet Gynecol 1993;82: 821–828.PubMedGoogle Scholar
  30. Whelan J III, Vlahos N. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883.PubMedCrossRefGoogle Scholar
  31. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. Part II. Am J Epidemiol 1992;136:1184–1203.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2002

Authors and Affiliations

  • Janee A. Fonslick
  • David B. Seifer

There are no affiliations available

Personalised recommendations